2018 年第 5 期 第 13 卷

茶碱缓释片联合沙美特罗替卡松粉吸入剂对慢性阻塞性肺疾病患者的疗效及对其生活质量的影响

Effect of theophylline sustained-release tablets combined with salmeterol xinafoate and fluticasone propionate inhalation on chronic obstructive pulmonary disease and quality of life

作者：赵波刘峰邹小广

英文作者：

单位：844000新疆维吾尔自治区喀什地区第一人民医院药学部

英文单位：

关键词：慢性阻塞性肺疾病；茶碱缓释片；沙美特罗替卡松粉吸入剂

英文关键词：

• 摘要：

• 目的    探讨茶碱缓释片联合沙美特罗替卡松粉吸入剂对慢性阻塞性肺疾病（COPD）患者的疗效及对患者生活质量的影响。方法    选取2016年7月至2017年5月在新疆维吾尔自治区喀什地区第一人民医院接受治疗的COPD患者74例，根据随机数表法将患者分为观察组和对照组，各37例。对照组患者给予沙美特罗替卡松粉吸入剂进行治疗，观察组在对照组基础上联用茶碱缓释片进行治疗，2组均连续治疗3个月。比较2组患者治疗前后的6 min步行距离、COPD自我评估测试评分、圣乔治呼吸问卷评分、第1秒用力呼气容积与用力肺活量比值、第1秒用力呼气容积占预计值百分比、深吸气量，比较2组患者不良反应发生情况。结果    治疗后观察组的6 min步行距离、第1秒用力呼气容积与用力肺活量比值、第1秒用力呼气容积占预计值百分比、深吸气量均明显长于/高于对照组［（326±14）m比（306±17）m、（61±9）%比（56±10）%、（49±9）%比（44±9）%、（2.1±0.4）L比（1.8±0.4）L］，COPD自我评估测试评分、圣乔治呼吸问卷各项评分（疾病症状评分、日常活动能力评分、疾病影响评分、总分）均明显低于对照组［（20.6±1.1）分比（23.5±1.2）分、（41±12）分比（47±12）分、（45±10）分比（53±10）分、（38±10）分比（43±10）分、（41±10）分比（47±11）分］（均P＜0.05）。观察组与对照组总不良反应发生率比较，差异无统计学意义（P＞0.05）。结论    茶碱缓释片联合沙美特罗替卡松粉吸入剂对COPD有较好的治疗效果，能显著改善患者的生活质量和肺功能，与单用沙美特罗替卡松粉吸入剂治疗相比联合用药优势明显。

• 【Abstract】Objective    To explore the effect of theophylline sustained-release tablets combined with salmeterol xinafoate and fluticasone propionate inhalation on chronic obstructive pulmonary disease(COPD) and quality of life. Methods    Totally 74 patients with COPD from July 2016 to May 2017 in the First People′s Hospital of Kashi were randomly divided into observation group and control group, with 37 cases in each group. The control group was treated with salmeterol xinafoate and fluticasone propionate inhalation; the observation group was treated with theophylline sustained-release tablets combined with salmeterol xinafoate and fluticasone propionate inhalation; both groups were treated for 3 months. Six minutes walk distance(6MWD), scores of the COPD Assessment Test(CAT) and the St George′s Respiratory Questionnaire(SGRQ), forced expiratory volume in 1 second to forced vital capacity ratio(FEV1/FVC), percentage of FEV1 in the predicted value(FEV1%), inspiratory capacit(IC) and adverse reactions were analyzed. Results    After treatment, 6MWD, FEV1/FVC, FEV1% and IC in observation group were significantly longer/higher than those in control group［（326±14）m vs （306±17）m, （61±9）% vs （56±10）%, （49±9）% vs （44±9）%, （2.1±0.4）L vs （1.8±0.4）L］; CAT score and SGRQ score (disease symptom score, activity of daily living score, disease impact score and total score) in observation group were significantly lower than those in control group［（20.6±1.1）vs（23.5±1.2）, （41±12）vs（47±12）, （45±10）vs（53±10）, （38±10）vs（43±10）, （41±10）vs（47±11）］(P＜0.05). Incidence of adverse reactions showed no significant difference between groups(P＞0.05). Conclusion    Theophylline sustained-release tablets combined with salmeterol xinafoate and fluticasone propionate inhalation has a good therapeutic effect on COPD; it can effectively improve lung function and quality of life.

  【Key words】Chronic obstructive pulmonary disease；Theophylline sustained-release tablets；Salmeterol xinafoate and fluticasone propionate inhalation

  【Fund program】Natural Science Foundation of Xinjiang Uygur Autonomous Region（2016D01C013）